Cargando…
ELABELA acts as a protective biomarker in patients with atrial fibrillation
BACKGROUND: Atrial fibrillation (AF) is the most common type of clinical arrhythmia. An early diagnosis can be beneficial in the prevention of complications, such as heart failure (HF) and stroke. In this study, we revealed that ELABELA (ELA) acts as a protective factor in patients with arrhythmia a...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743407/ https://www.ncbi.nlm.nih.gov/pubmed/35070372 http://dx.doi.org/10.21037/jtd-21-1728 |